Recent advancements in diabetes management have introduced a new class of drugs known as GLP-1 receptor agonists. These medications, which mimic the effects of a naturally occurring hormone called glucagon-like peptide-1 (GLP-1), offer a innovative approach to controlling blood sugar levels in individuals with diabetes. GLP-1 receptor agonists work

Emerging in the arena of excess body fat management, retatrutide is a distinct strategy. Beyond many existing medications, retatrutide works as a twin agonist, concurrently engaging both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The dual engagement encourages various beneficial effects, including b